Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN NASDAQ:FRMM NASDAQ:PLRX NYSEAMERICAN:PTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$6.06+4.7%$6.24$3.25▼$13.50$77.44M0.9199,421 shs103,257 shsFRMMForum Markets$5.58+7.3%$4.73$1.76▼$174.60$81.15M1.45295,558 shs419,739 shsPLRXPliant Therapeutics$1.14+0.9%$1.20$1.09▼$1.95$70.59M1.2453,797 shs321,031 shsPTNPalatin Technologies$11.44+11.6%$15.97$5.00▼$31.00$20.36M0.6320,309 shs28,853 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene0.00%+0.83%-9.55%+28.66%+47.80%FRMMForum Markets0.00%+10.50%+30.68%+557,999,900.00%+557,999,900.00%PLRXPliant Therapeutics0.00%-1.72%-8.80%-2.56%-17.39%PTNPalatin Technologies0.00%-2.39%-18.29%-42.77%+1,143,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$6.06+4.7%$6.24$3.25▼$13.50$77.44M0.9199,421 shs103,257 shsFRMMForum Markets$5.58+7.3%$4.73$1.76▼$174.60$81.15M1.45295,558 shs419,739 shsPLRXPliant Therapeutics$1.14+0.9%$1.20$1.09▼$1.95$70.59M1.2453,797 shs321,031 shsPTNPalatin Technologies$11.44+11.6%$15.97$5.00▼$31.00$20.36M0.6320,309 shs28,853 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene0.00%+0.83%-9.55%+28.66%+47.80%FRMMForum Markets0.00%+10.50%+30.68%+557,999,900.00%+557,999,900.00%PLRXPliant Therapeutics0.00%-1.72%-8.80%-2.56%-17.39%PTNPalatin Technologies0.00%-2.39%-18.29%-42.77%+1,143,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 2.71Moderate Buy$33.25448.68% UpsideFRMMForum Markets 2.50Moderate Buy$10.0079.21% UpsidePLRXPliant Therapeutics 1.80Reduce$3.00163.16% UpsidePTNPalatin Technologies 3.00Buy$55.00380.77% UpsideCurrent Analyst Ratings BreakdownLatest PTN, CLNN, FRMM, and PLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026FRMMForum Markets Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/26/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$5.00 ➝ $9.005/14/2026CLNNClene Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026FRMMForum Markets Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.005/11/2026FRMMForum Markets Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/8/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026CLNNClene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/4/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.00(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$200K387.23N/AN/A($1.62) per share-3.74FRMMForum Markets$6.55M12.39N/AN/A$12.59 per share0.44PLRXPliant Therapeutics$1.58M44.68N/AN/A$2.95 per share0.39PTNPalatin Technologies$4.49M4.54N/AN/A$5.95 per share1.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$26.17M-$3.20N/AN/AN/A-25,009.70%N/A-137.98%8/13/2026 (Estimated)FRMMForum Markets-$450.52M-$36.07N/A34.88N/AN/A-242.09%-135.46%N/APLRXPliant Therapeutics-$149.34M-$1.84N/AN/AN/AN/A-58.11%-44.37%8/6/2026 (Estimated)PTNPalatin Technologies-$17.31MN/AN/AN/AN/AN/A-141.40%-58.08%9/2/2026 (Estimated)Latest PTN, CLNN, FRMM, and PLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CLNNClene-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million5/14/2026Q1 2026FRMMForum MarketsN/A-$3.64N/A-$3.58N/A$2.86 million5/13/2026Q3 2026PTNPalatin Technologies-$1.2433-$0.37+$0.8733-$0.37$1.28 million$3.92 million5/11/2026Q1 2026PLRXPliant Therapeutics-$0.36-$0.32+$0.04-$0.32N/AN/A3/31/2026Q4 2025FRMMForum MarketsN/A-$12.14N/A-$12.24N/A$2.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/AFRMMForum MarketsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.941.93FRMMForum Markets0.156.196.19PLRXPliant TherapeuticsN/A16.8916.89PTNPalatin TechnologiesN/A5.045.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%FRMMForum Markets4.07%PLRXPliant Therapeutics97.30%PTNPalatin Technologies11.50%Insider OwnershipCompanyInsider OwnershipCLNNClene28.30%FRMMForum Markets15.10%PLRXPliant Therapeutics8.00%PTNPalatin Technologies7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene10012.78 million9.16 millionNo DataFRMMForum Markets714.54 million12.35 millionN/APLRXPliant Therapeutics9061.92 million56.97 millionOptionablePTNPalatin Technologies301.78 million1.65 millionN/APTN, CLNN, FRMM, and PLRX HeadlinesRecent News About These CompaniesPalatin to Begin Trading on Nasdaq Stock ExchangeMay 18, 2026 | prnewswire.comPalatin Is Betting on the Next Generation of Obesity Drugs (NYSE: PTN)May 14, 2026 | theglobeandmail.comPalatin Technologies, Inc. (AMEX:PTN) Q3 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comPalatin Technologies Earnings Call: Partnerships, Progress, RisksMay 13, 2026 | tipranks.comPalatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ...May 13, 2026 | finance.yahoo.comPalatin Technologies, Inc. (PTN) Q3 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comPalatin Technologies GAAP EPS of -$0.37, revenue of $3.9MMay 13, 2026 | seekingalpha.comPalatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdateMay 13, 2026 | prnewswire.comPalatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)March 22, 2026 | theglobeandmail.comPalatin Technologies, Inc. (PTN) Q2 2026 Earnings Call TranscriptFebruary 17, 2026 | seekingalpha.comPalatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdateFebruary 17, 2026 | prnewswire.comWhy Are Palatin Technologies (PTN) Shares Spiking After-Hours?December 11, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTN, CLNN, FRMM, and PLRX Company DescriptionsClene NASDAQ:CLNN$6.06 +0.27 (+4.66%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$6.06 0.00 (0.00%) As of 06/26/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Forum Markets NASDAQ:FRMM$5.58 +0.38 (+7.31%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$5.53 -0.05 (-0.88%) As of 06/26/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.Pliant Therapeutics NASDAQ:PLRX$1.14 +0.01 (+0.88%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$1.14 0.00 (0.00%) As of 06/26/2026 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Palatin Technologies NYSEAMERICAN:PTN$11.44 +1.19 (+11.61%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$12.17 +0.73 (+6.38%) As of 06/26/2026 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
